GLP-1 RA use linked to lower rates of hyperkalemia in type 2 diabetes

August 13 2024, by Elana Gotkine

Treatment with glucagon-like peptide 1 receptor agonists (GLP-1 RAs) is associated with lower rates of hyperkalemia and a lower rate of renin-angiotensin system inhibitor (RASi) discontinuation compared with
treatment with dipeptidyl peptidase-4 inhibitors (DPP-4is) among patients with type 2 diabetes (T2D), according to a study published online Aug. 12 in *JAMA Internal Medicine*.

Tao Huang, from Peking University in Beijing, and colleagues compared rates of hyperkalemia and RASi persistence among new users of GLP-1 RAs versus users of DPP-4is in a cohort study including adults with T2D who initiated GLP-1 RA or DPP-4i treatment between Jan. 1, 2008, and Dec. 31, 2021. Data were included for 33,280 individuals: 13,633 using GLP-1 RAs and 19,647 using DPP-4is.

The median time receiving treatment was 3.9 months. The researchers found that GLP-1 RA use was associated with a lower rate of any hyperkalemia and moderate-to-severe hyperkalemia compared with DPP-4i use (hazard ratios, 0.61 and 0.52, respectively).

Overall, 1,381 of the 21,751 participants using RASis discontinued this therapy. GLP-1 RA use was associated with a lower rate of RASi discontinuation compared with DPP-4i use (hazard ratio, 0.89). In intention-to-treat analyses and across strata of age, sex, cardiovascular comorbidity, and baseline kidney function, results were consistent.

"Treatment with GLP-1 RAs may enable wider use of the guideline-recommended cardioprotective and renoprotective medications and contribute to improving clinical outcomes in this population," the authors write.

**More information:** Tao Huang et al, GLP-1RA vs DPP-4i Use and Rates of Hyperkalemia and RAS Blockade Discontinuation in Type 2 Diabetes, *JAMA Internal Medicine* (2024). **DOI:** 10.1001/jamainternmed.2024.3806
Citation: GLP-1 RA use linked to lower rates of hyperkalemia in type 2 diabetes (2024, August 13) retrieved 14 August 2024 from https://medicalxpress.com/news/2024-08-glp-ra-linked-hyperkalemia-diabetes.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.